



## Haleon plc: Publication of Annual Report and Form 20-F 2024

**21 March 2025:** Haleon plc (the "Company") has published its Annual Report and Form 20-F for the year ended 31 December 2024 (the "Annual Report").

The Annual Report has been submitted to the National Storage Mechanism and is available for inspection at [data.fca.org.uk/#/nsm/nationalstoragemechanism](https://data.fca.org.uk/#/nsm/nationalstoragemechanism).

The Company has filed the Annual Report with the US Securities and Exchange Commission.

The Annual Report is publicly available on the Company's website at <http://www.haleon.com/investors/annual-report-2024>.

In compliance with the Disclosure Guidance and Transparency Rules, the Annual Report, as submitted to the National Storage Mechanism, contains regulated information in unedited full text and is available on the Company's website as noted above.

Shareholders may request a hard copy of the Annual Report, including the complete audited financial statements of the Company. Requests should be directed to: Company Secretariat, Haleon plc, Building 5, First Floor, The Heights, Weybridge, KT13 0NY, United Kingdom or to [corporate.secretariat@haleon.com](mailto:corporate.secretariat@haleon.com).

The Company's Annual General Meeting ("AGM") will take place on 28 May 2025. The Notice of AGM will be published and distributed to shareholders in due course.

**Amanda Mellor**  
**Company Secretary**

### About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit [www.haleon.com](http://www.haleon.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ACSMZGZFGGZGKZZ